Literature DB >> 6862366

Hemodynamic changes in patients with portal venous obstruction.

D Lebrec, C Bataille, E Bercoff, D Valla.   

Abstract

Splanchnic and systemic hemodynamics were evaluated in five adult patients with portal hypertension due to portal venous obstruction and were compared with those of patients with cirrhosis and those of a control group. In patients with portal venous obstruction, the gradient between wedged and free hepatic venous pressures ranged from 2 to 3 mm Hg, as in the control group, and was significantly lower than in patients with cirrhosis. Hepatic blood flow averaged 0.521 +/- 0.127 liter per min per m2 (mean +/- S.D.) and was significantly lower than that measured in cirrhotic and normal patients. Cardiac index averaged 3.788 +/- 0.629 liters per min per m2; this high value for cardiac index was not significantly different from that measured in cirrhotic patients, but was significantly higher than in patients of the control group. It is suggested that a hyperkinetic circulatory state may result from the development of portal-systemic venous collateral circulation in patients with portal venous obstruction having normal liver and hepatic venous pressures.

Entities:  

Mesh:

Year:  1983        PMID: 6862366     DOI: 10.1002/hep.1840030412

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

Review 1.  Pathophysiology and epidemiology of portal hypertension.

Authors:  H Okumura; T Aramaki; Y Katsuta
Journal:  Drugs       Date:  1989       Impact factor: 9.546

2.  Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension.

Authors:  M P Pizcueta; J M Piqué; J Bosch; B J Whittle; S Moncada
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

3.  The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.

Authors:  J Hasselström; S Eriksson; A Persson; A Rane; J O Svensson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

4.  Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis.

Authors:  A Braillon; P Cales; D Valla; D Gaudy; P Geoffroy; D Lebrec
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

5.  Relation of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels to growth retardation in extrahepatic portal vein obstruction.

Authors:  Lalit Nihal; Mukta R Bapat; Pravin Rathi; Nalini S Shah; Anjana Karvat; Philip Abraham; Shobna J Bhatia
Journal:  Hepatol Int       Date:  2008-09-20       Impact factor: 6.047

6.  Systemic and pulmonary hemodynamics in patients with extrahepatic portal vein obstruction is similar to compensated cirrhotic patients.

Authors:  Sanjeev Kumar Jha; Ashish Kumar; Barjesh Chander Sharma; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2008-12-06       Impact factor: 6.047

7.  Hemodynamic studies in a parabiotic model of portal hypertension.

Authors:  E Sikuler; R J Groszmann
Journal:  Experientia       Date:  1985-10-15

8.  Surgical complications following liver transplantation in patients with portal vein thrombosis--a single-center perspective.

Authors:  Rajeev Sharma; Randeep Kashyap; Ashok Jain; Saman Safadjou; Maureen Graham; Alok Kumar Dwivedi; Mark Orloff
Journal:  J Gastrointest Surg       Date:  2009-12-04       Impact factor: 3.452

9.  Hepatic siderosis in extrahepatic portal vein obstruction. Role of spontaneous portosystemic shunting?

Authors:  J P Capron; A Remond; J L Dupas; H Mancheron; D Capron-Chivrac; A Brailon
Journal:  Dig Dis Sci       Date:  1986-08       Impact factor: 3.199

Review 10.  What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective.

Authors:  Francesca Romana Ponziani; Maria Assunta Zocco; Matteo Garcovich; Francesca D'Aversa; Davide Roccarina; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.